Jonathan W. Friedberg

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial

Jeremy Abramson, Susan Geyer, Sharmila Giri, Levi Pederson et autres

us (code pays fourni par la source)

Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

Sairah Ahmed, Hongli Li, Alex F. Herrera, Anamarija M. Perry et autres

Classic Hodgkin lymphoma (cHL) associated with Epstein-Barr virus (EBV) positivity as well as non-nodular sclerosis (non-NS) histologic subtypes have demonstrated poorer outcomes compared to EBV-negative and nodular sclerosis cases. We report a prespecified subset analysis of patients enrolled in the phase III …

us, ca (code pays fourni par la source)

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma

Jonathan W. Friedberg

us (code pays fourni par la source)

Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma

Zhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, Lasse Jakobsen et autres

One quarter of patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response following front-line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended …

us, dk, se (code pays fourni par la source)

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy

Prokop Vodička, Tarec C El-Galaly, Vít Procházka, Christopher R. Flowers et autres

ABSTRACT: A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.

cz, us, dk, se, ca, fr, au (code pays fourni par la source)

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty

Patrick M. Reagan, Allison Magnuson, Craig A. Portell, Andrea Baran et autres

us (code pays fourni par la source)

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy

Mazyar Shadman, Michael LeBlanc, Lisa M. Rimsza, John P. Leonard et autres

Importance: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. Objective: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with …

us (code pays fourni par la source)

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

Daniel Filip, Katerina Musilova Litzmanova, Androniki Michaelou, Filip Kledus et autres

Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first …

cz, at, us, de (code pays fourni par la source)

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study

Jia Ruan, Zhengming Chen, Melissa C Larson, N Nora Bennani et autres

ABSTRACT: Few prospective benchmark studies exist to characterize the evolving contemporary real-world practice for peripheral T-cell lymphoma (PTCL). We report the patterns of first-line care and outcomes for 720 patients with systemic PTCL enrolled in 2 related prospective cohort studies, Lymphoma Epidemiology …

us (code pays fourni par la source)

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Eva Domingo-Domenech, Barbara Pro, Tim Illidge, Steven Horwitz et autres

Following the publication of this article, the authors noted the following sentence could be misinterpreted: ‘In patients with ALK– sALCL, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5–70.2%) and 56.0% (39.3–69.7%) in the A + CHP and CHOP arms, respectively’. …

es, us, gb, de, dk, kr, jp, it, cz, hu, fr, ie, ca (code pays fourni par la source)

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

Sharon M. Castellino, H. Li, Alex F. Herrera, Michael LeBlanc et autres

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients …

us, ca (code pays fourni par la source)

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma

Gaurav Goyal, Kathryn Lurain, Gabby Lopez, Sarah C. Rutherford et autres

PURPOSE: S1826 was an international phase 3 randomized trial that demonstrated improved progression-free survival of nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) over brentuximab vedotin plus AVD (BV+AVD) in newly diagnosed advanced stage classic Hodgkin lymphoma (cHL). Here we report results of …

us, ca (code pays fourni par la source)